Platelet-activating Factor–mediated NF-κB Dependency of a Late Anaphylactic Reaction by Choi, Il-Whan et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2003/07/145/7 $8.00
Volume 198, Number 1, July 7, 2003 145–151
http://www.jem.org/cgi/doi/10.1084/jem.20022129
 
145
 
Platelet-activating Factor–mediated NF-
 
 
 
B Dependency of a 
Late Anaphylactic Reaction
 
Il-Whan Choi,
 
1
 
 Young-Suk Kim,
 
1
 
 Dae-Ki Kim,
 
1
 
 Jung-Hwa Choi,
 
3
 
Kook-Heon Seo,
 
3
 
 Shun-Young Im,
 
3
 
 Keun-Sang Kwon,
 
2
 
 Myung-Shik Lee,
 
4
 
 
 
Tai-You Ha,
 
1
 
 and Hern-Ku Lee
 
1
 
1
 
Department of Immunology and 
 
2
 
Department of Preventive Medicine, Chonbuk National University Medical 
School, Chonju 561-180, South Korea
 
3
 
Department of Biological Sciences, College of Natural Sciences, Chonnam National University, Kwangju 500-757, 
South Korea
 
4
 
Department of Medicine, Samsung Medical Center, Sungkyunkwan University College of Medicine, 
Seoul 135-710, South Korea
 
Abstract
 
Anaphylaxis is a life-threatening systemic allergic reaction with the potential for a recurrent or
biphasic pattern. Despite an incidence of biphasic reaction between 5 and 20%, the molecular
mechanism for the reaction is unknown. Using a murine model of penicillin V–induced sys-
temic anaphylaxis, we show an autoregulatory cascade of biphasic anaphylactic reactions. In-
duction of anaphylaxis caused a rapid increase in circulating platelet-activating factor (PAF)
levels. In turn, the elevated PAF contributes to the early phase of anaphylaxis as well as the sub-
sequent activation of the nuclear factor (NF)-
 
 
 
B, a crucial transcription factor regulating the
expression of many proinflammatory cytokines and immunoregulatory molecules. The induc-
tion of NF-
 
 
 
B activity is accompanied by TNF-
 
 
 
 production, which, in turn, promotes late
phase PAF synthesis. This secondary wave of PAF production leads eventually to the late phase
of anaphylactic reactions. Mast cells do not appear to be required for development of the late
phase anaphylaxis. Together, this work reveals the first mechanistic basis for biphasic anaphy-
lactic reactions and provides possible therapeutic strategies for human anaphylaxis.
Key words: early anaphylaxis • biphasic anaphylaxis • mast cell • penicillin V • TNF-
 
 
 
Introduction
 
Anaphylaxis is a life-threatening systemic allergic reaction
triggered by food antigens, medications or drugs, insect
venom, and many other agents. Anaphylaxis has been
shown to have the potential for a recurrent or biphasic
pattern with an incidence between 5 and 20% (1–4). A
few papers regarding biphasic reaction reveal that the re-
currence can be severe enough to necessitate intubation
and treatment with vasopressor agents (1, 4). These obser-
vations require that patients should be followed carefully
after an apparent remission of an anaphylactic event.
The early anaphylactic reaction is thought to be caused
by the release of platelet-activating factor (PAF),
 
*
 
 hista-
mine, serotonin, or many other chemical mediators from
mast cells and basophils after antigen–antibody interactions
(5). In a murine model of anaphylaxis, the major cause of
fatal reaction is hypovolemic shock (6). PAF, a potent lipid
messenger with diverse biological activities (7), is thought
to be critical in the development of the hypovolemic
shock. PAF antagonists can prevent fatal anaphylaxis by
correcting PAF-induced hypovolemia (8, 9). However, the
downstream pathways beyond the PAF-induced early reac-
tion are unknown.
PAF is also known to play an important in vivo role in
the initiation of inflammatory reactions through activation
of nuclear factor (NF)-
 
 
 
B (10–12), a pivotal transcription
factor responsible for regulating the expression of proin-
flammatory cytokines and many immunoregulatory mole-
cules (13, 14). NF-
 
 
 
B is necessary for optimal expression of
the proinflammatory cytokines TNF-
 
 
 
 and IL-1, which
promote further synthesis of PAF, thus completing a posi-
tive feedback system (15, 16). Therefore, it is intriguing to
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speculate that PAF-induced NF-
 
 
 
B–dependent release of
inflammatory mediators, such as TNF-
 
 
 
 and IL-1, may
associate with development of the late phase of anaphy-
laxis. Using a murine model of penicillin V–induced sys-
temic anaphylaxis (17, 18), we demonstrate in this work
that the overall biphasic anaphylaxis is coincident with a
biphasic increase of circulating PAF. The early release of
PAF in response to the challenge injection induces a late
or secondary synthesis of PAF through pathways involv-
ing NF-
 
 
 
B activation.
 
Materials and Methods
 
Animals. 
 
Specific pathogen-free male C57BL/6 mice were
obtained from the Korean Institute of Chemistry Technology,
and were housed in a laminar flow cabinet and maintained on
standard laboratory chow ad libitum. TNF
 
-
 
 
 
 knockout mice (B6:
129S-Tnftm1Gk1, TNF-
 
 
 
 
 
/
 
 
 
), IL-1 receptor knockout mice
(B6: 129S-Il1r1tm1Rom1, IL-1R
 
 
 
/
 
 
 
), and the original wild-type
strain (B6129SF2/J) were obtained from the Jackson Laboratory.
Female mast cell–deficient WBB6F1-
 
W/W
 
v
 
 (
 
W/W
 
v
 
) and mast
cell–sufficient control WBB6F1-
 
 
 
/
 
 
 
 mice were purchased from
the Japan SLC Inc. Mice were 7–8-wk-old at the start of each ex-
periment.
 
Induction of Active Systemic Anaphylaxis to Penicillin (Pen) V.
 
Mice were sensitized by i.p. injection of 500 
 
 
 
g Pen V–OVA
conjugate plus 2 
 
 
 
 10
 
9
 
 
 
B. pertussis
 
 and 1.0 mg alum (17, 18). The
challenge was performed 21 d later by giving i.v. injection of a
sublethal dose (10–20 
 
 
 
g) of Pen V–BSA conjugate.
 
Reagents. 
 
The PAF antagonist WEB 2170 was provided by
Dr. C.K. Lee (Dankook University College of Medicine, Seoul,
Korea) and CV 6209 was purchased from WAKO Chemical Co.
12.5 mg/kg WEB 2170 and 15.0 mg/kg CV 6209 were adminis-
tered i.p. either 10 min before or 6 h after the challenge injection.
0.5 mg/kg 
 
N
 
-acetyl-
 
l
 
-cysteine (NAC) and 120 mg/kg pyrroli-
dine dithiocarbamate (PDTC) were administered i.p. 2 h and 30
min before challenge, respectively. Control groups received the
appropriate vehicles. Anti–TNF-
 
 
 
 (MP6-XT22.11, rat IgG1;
reference 19) and control rat IgG1, J4-1 (17), were injected i.p.
45 min after challenge.
 
Hematocrit Assay. 
 
Anaphylaxis was quantified by measuring
the increase in hematocrit value as described previously (20).
Small blood samples were collected from the heart, which was
cut open into a heparinized microhematocrit tube (Proper Manu-
facturing Co.). The tubes were centrifuged for 5 min using mi-
crohematocrit centrifuge (International Equipment Co.). Percent
hematocrit change was expressed as [(value at postchallenge 
 
 
 
value at prechallenge)/value at prechallenge] 
 
 
 
 100.
 
Plasma PAF and Histamine Assay. 
 
The postchallenge blood
taken from the heart was mixed with a 0.1-vol 3.8% ice-chilled
citrate solution and centrifuged immediately using an Eppendorf
microcentrifuge. The plasma was stored at 
 
 
 
20
 
 
 
C until use.
Plasma levels of PAF and histamine were measured as described
previously (18).
 
Gel Shift Assay. 
 
The nuclear extracts were prepared from
the lungs as described previously (10–12). To inhibit endogenous
protease activity, 1 mM phenylmethylsulfonyl fluoride was
added. As a probe for the gel retardation assay, oligonucleotides
containing the Ig
 
 
 
-chain binding site (
 
 
 
B, 5
 
 
 
-CCGGTTAACA-
GAGGGGGCTTTCCGAG-3
 
 
 
) and cyclic AMP response ele-
ment (CRE) sequence (5
 
 
 
-AGAGATTGCCTGACGTCAGAG
AGCTAG-3) were synthesized. The two complementary strands
were annealed and labeled with 
 
 
 
-[
 
32
 
P]dCTP. Labeled oligonu-
cleotides (10,000 cpm), 10 
 
 
 
g of nuclear extracts, and the bind-
ing buffer (10 mM Tris-HCl, pH 7.6, 500 mM KCl, 10 mM
EDTA, 50% glycerol, 100 ng of poly (dI 
 
 
 
 dC), and 1 mM DTT)
were incubated for 30 min at room temperature in a final volume
of 20 
 
 
 
l. The reaction mixture was analyzed by electrophoresis
on a 4% polyacrylamide gel in 0.5
 
 
 
 TBE buffer. Specific binding
of NF-
 
 
 
B was determined by competition with a 50-fold excess
of cold 
 
 
 
B or CRE oligonucleotide.
 
Reverse Transcriptase–PCR. 
 
Total RNA was prepared at dif-
ferent time points from the lungs by a single extraction based on
the guanidine isothiocyanate extraction method with the dena-
turing solution (Sol. D) consisting of 4 M guanidinium thiocyan-
ate, 25 mM sodium citrate, pH 7.0, 0.5% sarcosyl, and 0.1 M
2-mercaptoethanol (21). Reverse transcription was performed us-
ing 1 
 
 
 
l total RNA in a 10-
 
 
 
l reaction mixture (Promega) con-
taining oligo (dT)
 
15
 
 and avian myeloblastosis reverse transcriptase.
1 
 
 
 
l cDNA was amplified by PCR in a thermal cycler (denatur-
ation for 30 s at 95
 
 
 
C, annealing for 30 s at 62
 
 
 
C, and elongation
for 30 s at 72
 
 
 
C; PerkinElmer) using 25 cycles for each of three
primers: TNF-
 
 
 
, IL-1
 
 
 
, or 
 
 
 
-actin. The primers used in this
analysis are as follows: TNF-
 
 
 
, 5
 
 
 
-CCTGTAGCCCACGTCG-
TAGC-3
 
 
 
 and 5
 
 
 
-TTGACCTCAGCGCTGATGTG-3
 
 
 
; IL-1
 
 
 
,
5
 
 
 
-GATACAAACTGATGAAGCTCGTCA-3
 
 
 
 and 5
 
 
 
-GAGA-
TAGTGTTTGTCCACATCCTGA-3
 
 
 
; and 
 
 
 
-actin, 5
 
 
 
-GGG-
TCAGAACTCCTATG-3
 
 
 
 and 5
 
 
 
-TTGACCTCAGCGCTGA-
TGTG-3
 
 
 
.
 
Measurement of Pen V–Specific Serum Levels of IgE. 
 
Pen V–spe-
cific serum IgE levels were determined by a passive cutaneous ana-
phylaxis reaction as described previously (18). In brief, serial dilu-
tions of individual sera from mice immunized with Pen V–OVA
were injected intracutaneously into the shaved backs of male
Wistar rats (Japan SLC). After 24 h, 1 ml of 1% Evan’s blue dye in
PBS containing 4 mg Pen V–BSA was injected i.v. The rats were
killed 30 min later, their skins were removed, and the blue spot
with diameter 
 
 
 
5 mm was regarded as a positive reaction.
 
Cytokine Assay. 
 
Serum levels of TNF-
 
 
 
 and IL-1
 
 
 
 were de-
termined using ELISA kits (Endogen) according to the manufac-
turer’s instructions.
 
Results
 
Occurrence of Biphasic Anaphylactic Events Coincident with a
Biphasic Increase in Circulating PAF Levels.
 
First, we exam-
ined whether a systemic biphasic reaction occurs in mice
undergoing anaphylaxis. Anaphylaxis was monitored by
measuring increases in hematocrit because hemoconcentra-
tion, which occurs due to extravasation of plasma, is the
most prominent symptom in murine anaphylaxis (6). A bi-
phasic increase in hematocrit (Ht) was observed in mice
undergoing active systemic anaphylaxis (Fig. 1 a). The se-
vere early hemoconcentration began within 2–3 min after
challenge, peaked (40% increase) at 10–20 min, and subse-
quently returned to prechallenge values at 5–6 h. From
these values, it could be calculated that 70–80% blood vol-
ume had disappeared from the circulation. A substantial
second phase of hemoconcentration, albeit to a lesser de-
gree relative to the duration and severity of the first, was
evident 7–8 h after challenge. In this secondary phase of
anaphylaxis, hematocrits increased by 20%, which repre-
sents a loss of 
 
 
 
35–40% of the initial blood volume.T
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PAF is the crucial molecule responsible for murine ana-
phylactic reactions (8, 9, 18). To assess the association of
PAF with the biphasic reaction, the PAF antagonists WEB
2170 and CV 6209 were used. Pretreatment with the an-
tagonists before challenge abrogated the early as well as late
phase of hemoconcentration (Fig. 1 a). The degree of inhi-
bition of the early hemoconcentration reaction in the
group receiving PAF antagonists was mirrored in their ef-
fect on other general anaphylactic symptoms, including
sluggish gate, paresis, and prostration (unpublished data).
Furthermore, PAF antagonists administered 6 h after chal-
lenge completely blocked the secondary phase of hemo-
concentration (Fig. 1 b), which strongly suggests that PAF
is also responsible for a second wave of anaphylactic events.
The time course of plasma levels of PAF during anaphylaxis
paralleled those of the biphasic anaphylactic reactions, with
the major early peak appearing within 5–10 min followed
by a small second PAF peak 
 
 
 
7.0–7.5 h (Fig. 1 c). Collec-
tively, these data suggest that the overall process of biphasic
anaphylactic reactions is multiphasic with the initial release
of PAF acting as an inducer for the next. In turn, this leads
to systemic anaphylactic reaction that is also biphasic.
 
NF-
 
 
 
B Activity Is Required for the Secondary Increase in
Plasma PAF and Hematocrit.
 
PAF is a potent inducer of
NF-
 
 
 
B in vitro as well as in vivo (10–14). We measured
NF-
 
 
 
B activity during anaphylaxis by a gel mobility shift
assay. Induction of systemic anaphylaxis resulted in NF-
 
 
 
B
activation in the lung (Fig. 2 a). NF-
 
 
 
B activity appeared
within 30 min of the challenge. A similar pattern of NF-
 
 B
activation was also observed in the liver and spleen (unpub-
lished data). Pretreatment of animals with PAF antagonists
resulted in an almost complete inhibition of NF- B activa-
tion (Fig. 2 a), confirming that PAF is responsible for the
activation of NF- B during anaphylaxis. To block NF- B
activation, we used the antioxidant, NAC and PDTC.
NAC and PDTC also significantly inhibited NF- B activa-
tion (Fig. 2 a). Complete blocking of NF- B mobilization
by adding the cold competitor, but not by adding of an ir-
relevant motif, CRE, indicated the specificity of NF- B
binding. In addition, NAC had no effect on CRE mobili-
zation, further demonstrating the specificity of the inhibi-
tors (Fig. 2 a). Next, we examined the possible association
of NF- B activity with the late anaphylactic reactions.
Both NF- B inhibitors significantly inhibited the second
phase of increased plasma PAF levels (Fig. 2 b) and hemat-
ocrit (Fig. 2 c). However, the NF- B inhibitors did not in-
hibit the first phase of increase in PAF release and hemo-
concentration (unpublished data).
NF- B–dependent TNF-  Production Leads to the Second
Phase of Hemoconcentration through the Synthesis of PAF.
The activation of NF- B results in the expression of proin-
flammatory cytokine genes, such as TNF-  and IL-1 (13,
14). Therefore, we investigated whether TNF-  and IL-1
are produced in an NF- B–dependent manner during ana-
phylaxis. Serum TNF-  levels peaked 1–1.5 h after chal-
lenge (Fig. 3 a) and declined rapidly thereafter. In contrast,
IL-1 was not detected in the circulation during the obser-
vation period. The administration of a PAF antagonist and
an NF- B inhibitor nearly completely inhibited the in-
Figure 1. Induction of sys-
temic anaphylaxis results in PAF-
associated biphasic anaphylaxis.
(a) Biphasic increase in hemat-
ocrit (Ht) values during anaphy-
laxis and its inhibition by the
PAF antagonists WEB 2170 ( )
and CV 6209 ( ) administered
10 min before challenge injec-
tion.  , control group. (b) Inhi-
bition of the late phase increase
in hematocrit values by WEB
2170 ( ) and CV 6209 ( ).
They were administered 6 h after
challenge injection.  , control
group. (c) Biphasic increase in
plasma PAF levels during ana-
phylaxis. Results for all panels
are expressed as the mean  
SEM of three to seven separate
experiments (n   4 for each time
point). *, P   0.05; **, P   0.01
versus control. Statistical signifi-
cance was determined by Mann-
Whitney U test.
Figure 2. PAF-induced activation of NF- B during anaphylaxis and its
association with the development of the late phase of anaphylaxis. (a)
NF- B activation during anaphylaxis and its inhibition by the pretreat-
ment with PAF antagonists and NF- B inhibitors. After the challenge,
lungs were removed at the indicated time points and the time course of
NF- B activation was measured by gel shift assay with nuclear extracts
(n   3–5 for each time point). For gel shift assay of CRE mobilization,
lungs were removed 1 h after challenge. A representative of four indepen-
dent experiments is shown. (b and c) Inhibition of the second phase of in-
crease in plasma PAF (b) and hematocrit value (c) by NF- B inhibitors.
Blood was collected 7.5 h after the challenge. Results for all panels are ex-
pressed as the mean   SEM of three to seven separate experiments (n   4
for each time point). *, P   0.01 versus control; Mann-Whitney U test.T
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crease in serum TNF-  levels after the challenge (Fig. 3 b),
indicating that production of TNF-  during anaphylaxis is
a PAF-induced NF- B–dependent process.
To assess the possibility that TNF-  produced after the
early anaphylactic response is involved in the secondary
increase in plasma PAF concentration and hemoconcen-
tration, anti–TNF-  Ab-treated and TNF-  /  mice
were challenged to induce anaphylaxis. Treatment with
anti–TNF- , MP6-XT22.11 (19), resulted in a dose-
dependent inhibition of the secondary increase in plasma
PAF (Fig. 3 c) and hemoconcentration (Fig. 3 d). At a
concentration of 2 mg/mouse, anti–TNF-  almost com-
pletely inhibited the responses. We further examined the
role for TNF-  in the development of the late phase of
anaphylaxis using TNF-  /  mice. Given the fact that
TNF- –deficient mice exhibit abnormal antibody class
switching (including IgE) due to a failure of germinal cen-
ter formation (22), we first examined Pen V–specific IgE
response in TNF- –deficient mice. The Pen V–specific
IgE level in TNF- –deficient mice was  25% of control
littermates (Fig. 3 e). Despite the reduced IgE response, a
similar magnitude of the early phase of anaphylaxis devel-
oped in both control littermates and TNF-  /  mice (Fig.
3 f). In contrast, TNF-  /  mice exhibited little increase
in the late phase plasma PAF concentration and hematocrit
(Fig. 3 f). Given our previous information that a fatal Pen
V–induced anaphylaxis occurs in mice of which Pen V–spe-
cific IgE level is reduced to 10% of control mice (17), the
IgE level in TNF- –deficient mice seems to be sufficient
to induce anaphylaxis. Furthermore, when the mice were
challenged with a lethal dose of antigen (100  g Pen
V–BSA), a similar mortality rate was observed in control
littermates (9/10) and TNF- –deficient mice (8/10; un-
published data). These data indicate that TNF-  is associ-
ated with the late phase of anaphylaxis through the syn-
thesis of PAF.
Although IL-1 was not detected in the circulation dur-
ing anaphylaxis by ELISA system, it is thought that even
femtograms per milliliter of IL-1 can have pathophysio-
logical activities (23, 24). Thus, to further clarify the role
for IL-1 during anaphylaxis, we determined TNF-  and
IL-1  mRNA levels in the lungs. A much weaker IL-1 
mRNA expression was seen compared with the strong
expression of TNF-  mRNA during anaphylaxis (Fig. 4
a). In contrast, LPS-induced IL-1  mRNA expression
was comparable to that of TNF-  mRNA. Furthermore,
similar levels of plasma PAF and hematocrit in the late
phase were seen in IL-1R    mice (Fig. 4 b). These data
indicate that IL-1 does not seem to play a significant role
in Pen V–induced anaphylaxis.
Mast Cells Are Not Involved in the Late Phase of Anaphy-
laxis. To investigate a role for mast cells in the develop-
ment of the late anaphylactic reactions, we determined the
time course of plasma histamine levels after the challenge
and examined whether the late anaphylactic reaction oc-
Figure 3. Involvement of TNF-  in the development of the late ana-
phylactic reactions. (a) Time course of serum levels of TNF-  ( ) and
IL-1 ( ) during anaphylaxis. (b) TNF-  inhibition by pretreatment with
CV 6209 ( ) and PDTC ( ).  , control group. (c and d) Inhibition of
the late phase increase in plasma PAF (c) and hematocrit value (d) by
anti–TNF-  Ab ( ).  , control Ab. Abs were injected i.p. 45 min after
challenge injection. Blood was collected 7.5 h after the challenge. (e) Se-
rum levels of Pen V–specific IgE. Blood samples were taken 1 d before
challenge. (f) No late phase increase in plasma PAF and hematocrit value
in TNF-     mice ( ).  , control littermates. Blood was collected 7.5 h
after the challenge. Results for all panels are expressed as the mean  
SEM of three separate experiments (n   4 for each time point). **, P  
0.05; *, P   0.01 versus control; Mann-Whitney U test.
Figure 4. IL-1 is not an im-
portant mediator in developing a
late phase anaphylactic reaction.
(a) Comparison of mRNA ex-
pression between TNF-  and
IL-1  during anaphylaxis. As a
positive control, RNA was pre-
pared at different time points
from the lungs of 50- g LPS-
injected mice. (b) The late phase
increase in plasma PAF and
hematocrit value in IL-1R / 
mice. Blood was collected 7.5 h
after challenge injection. Results
for all panels are expressed as the
mean   SEM of three separate
experiments (n   3 for each time
point).T
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curs in mast cell–deficient WBB6F1-W/Wv ( W/Wv)
mice. Levels of circulating histamine reached a peak
within 10 min, but rapidly declined thereafter and re-
mained within the basal level during the observation pe-
riod (Fig. 5 a). The late anaphylactic reactions such as
increases in plasma PAF concentration and hemoconcen-
tration developed to a similar degree in both mast cell–
sufficient control  /  and W/Wv mice (Fig. 5 b). From
these data, mast cells do not appear to be required for de-
velopment of the late anaphylactic reaction. Because mast
cells are one source of both the cytokines TNF-  and IL-1
(25), we examined the circulating TNF-  levels during
anaphylaxis in W/Wv mice. W/Wv mice were defective in
producing TNF-  as W/Wv mice possess 20–30% of the
wild-type level (Fig. 5 c). Circulating IL-1  was not de-
tected in W/Wv mice during anaphylaxis (unpublished
data). This reduced level of TNF-  in W/Wv mice seems
to be due to the lower level of circulating PAF during
anaphylaxis (18) and the absence of mast cell–derived
TNF- . Pretreatment with anti–TNF-  resulted in abro-
gation of the late increase in hematocrit in both wild-type
and  W/Wv mice (Fig. 5 d). Therefore, it is likely that
TNF-  is also a key cytokine in the development of a late
anaphylactic reaction in W/Wv, even with a reduced ca-
pacity to produce this cytokine.
Discussion
In a murine model of anaphylaxis, we were successful in
demonstrating a biphasic systemic anaphylaxis and in de-
scribing an underlying molecular cascade. The early reac-
tion is caused by the acute release of PAF, reaching a
maximum 10 min after challenge. The first PAF wave
eventually contributes to development of a late or second-
ary reaction by activating a sequential pathway involving
NF- B activation, TNF-  production, and a secondary
phase of PAF synthesis. The secondary phase of PAF syn-
thesis is responsible for eliciting the late phase reactions.
Thus, overall, a biphasic reaction is coincident with a bi-
phasic increase of circulating PAF.
PAF, produced by a variety of cells involved in inflam-
matory reactions, is a potent lipid messenger involved in a
diverse inflammatory reactions (7) and cellular functions
(26–28). Our studies have demonstrated that PAF acts as a
potent inducer of NF- B activation, leading to gene ex-
pression and protein synthesis of NF-kB–dependent cyto-
kines in many pathological conditions, such as inflamma-
tion (10, 11), microbial infection (12), and angiogenesis
(29). Therefore, PAF may be the most proximal mediator
responsible for the pathogenesis of diseases in which NF-
 B activity plays an important role.
We demonstrate for the first time an association of
PAF-induced NF- B activation with the late anaphylactic
reactions. The late synthesis of PAF is in response to the
presence of TNF- , which was produced as a conse-
quence of NF- B activation. Regarding the molecules in-
volved in the late phase of allergic reaction, TNF-  has
been shown to participate in IgE-dependent cutaneous
late phase reactions (30), which further supports the im-
portance of TNF-  in the development of late phase reac-
tions. NF- B–dependent proinflammatory cytokines, such
as TNF-  and IL-1, are known to stimulate the synthesis
of PAF. In fact, many in vivo biological functions of
TNF-  are mediated through the synthesis of PAF (31–
33). Although the mechanism for TNF- –induced PAF
synthesis is not fully understood, it seems likely that TNF- 
exerts its effect via a pathway involving phospholipase A2
(PLA2); given that TNF-  has been shown to enhance
PLA2 activity (34, 35). An increase in PLA2 activity would
lead to the biosynthesis of arachidonic acid metabolites,
such as prostaglandins, leukotrienes, and PAF (36, 37). We
also observed that the late phase increase in plasma PAF
and hemoconcentration was completely inhibited by the
PLA2 inhibitor, quinacrine (unpublished data), supporting
the possibility that PLA2 activity is also an important com-
ponent of the cascade leading to development of the late
phase of anaphylaxis.
Mast cells have long been believed to be the central ef-
fector cells in the development of IgE-dependent anaphy-
laxis, although early immediate hypersensitivity reactions to
protein antigens as well as hapten can be developed in
W/Wv mice (18, 38). The current paper showing an early
single peak in plasma histamine level and similar late reac-
tions in magnitude and kinetics in both  /  and W/Wv
Figure 5. Mast cells are not involved in the late phase of anaphylaxis.
(a) Time course of plasma histamine levels after challenge in C57BL/6
mice. (b) The late phase increase in plasma PAF and hematocrit value in
W/Wv mice. Blood was collected 7.5 h after challenge injection. (c)
Comparison of serum levels of TNF-  between     and W/Wv mice
during anaphylaxis. Blood was collected 80 min after challenge injection.
(d) Inhibition of the second phase of increase in hematocrit value by anti–
TNF-  Ab. 2 mg/mouse Ab was injected i.p. 45 min after challenge in-
jection. Results for all panels are expressed as the mean   SEM of three
separate experiments (n   3 for each time point). P   0.01 versus con-
trol; Mann-Whitney U test.T
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mice suggests that other inflammatory cells rather than mast
cells participate in the late phase of anaphylaxis.
Currently, there is no evidence whether the same mech-
anisms are also in play in human anaphylaxis. However,
based on the information that a late or secondary phase of
human anaphylactic symptoms such as urticaria, rash, and
hypotension develop after at least 5–6 h of lag period after
the onset of anaphylaxis (4), it seems likely that a second
wave of synthesis of chemical mediators also occurs in hu-
man anaphylaxis. Thus, it is plausible that a similar mecha-
nism may operate in human anaphylaxis in terms of the in-
volvement of NF- B–induced proinflammatory cytokine
expression resulting in the late synthesis of mediators such
as PLA2-dependent arachidonic acid metabolites and PAF.
If that is the case, selective inhibitors that target the various
components of the pathway (for example, anti–TNF-  Ab
or PLA2 inhibitor) might be of a great therapeutic value for
controlling the late phase of human anaphylaxis.
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